{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:57:39Z","timestamp":1785513459270,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-08153-9","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:56:29Z","timestamp":1785466589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug price"],"prefix":"10.1007","author":[{"given":"Edward","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Mirzayeh Fashami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"McTavish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0782-8816","authenticated-orcid":false,"given":"Marion","family":"Schauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"8153_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102","journal-title":"Osteoporos Int"},{"key":"8153_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-016-0285-0","volume":"11","author":"AA Yusuf","year":"2016","unstructured":"Yusuf AA, Matlon TJ, Grauer A, Barron R, Chandler D, Peng Y (2016) Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries. Arch Osteoporos 11:1\u20137","journal-title":"Arch Osteoporos"},{"key":"8153_CR3","first-page":"1813","volume":"10","author":"ES Siris","year":"2015","unstructured":"Siris ES, Yu J, Bognar K, DeKoven M, Shrestha A, Romley JA, Modi A (2015) Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage. Clin Interv Aging 10:1813\u20131824","journal-title":"Clin Interv Aging"},{"key":"8153_CR4","doi-asserted-by":"crossref","unstructured":"Singer A, Exuzides A, Spangler L, O\u2019Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clinic Proceedings. Elsevier, pp 53\u201362","DOI":"10.1016\/j.mayocp.2014.09.011"},{"key":"8153_CR5","volume":"3","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Ortendahl JD, Vanderpuye Orgle J, Grauer A, Arellano J, Lemay J, Harmon AL, Broder MS, Singer AJ (2019) Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States. J Bone Miner Res Plus 3:e10192","journal-title":"J Bone Miner Res Plus"},{"key":"8153_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-016-0272-5","volume":"11","author":"BR Lindsay","year":"2016","unstructured":"Lindsay BR, Olufade T, Bauer J, Babrowicz J, Hahn R (2016) Patient-reported barriers to osteoporosis therapy. Arch Osteoporos 11:1\u20138","journal-title":"Arch Osteoporos"},{"key":"8153_CR7","unstructured":"Food and Drug Administration (1995) FDA label for Fosamax."},{"key":"8153_CR8","unstructured":"Food and Drug Administration (2010) FDA label for Prolia."},{"key":"8153_CR9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R, Ebeling PR, Jan De Beur S, Langdahl B, Rhee Y, Fuleihan GE-H, Kiel DP, Schousboe JT (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res 39:1393\u20131405","journal-title":"J Bone Miner Res"},{"issue":"1","key":"8153_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11657-017-0316-5","volume":"12","author":"E Durden","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteopor 12(1):22","journal-title":"Arch Osteopor"},{"key":"8153_CR11","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1210\/jc.2018-02236","volume":"104","author":"H Lyu","year":"2019","unstructured":"Lyu H, Jundi B, Xu C, Tedeschi SK, Yoshida K, Zhao S, Nigwekar SU, Leder BZ, Solomon DH (2019) Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 104:1753\u20131765","journal-title":"J Clin Endocrinol Metab"},{"key":"8153_CR12","unstructured":"IBM Micromedex Red Book (2024) Red Book. IBM Watson Health\u2122, an IBM Company,"},{"key":"8153_CR13","unstructured":"Association for Accessible Medicines (2024) The U.S. generic & biosimilar medicines savings report. https:\/\/accessiblemeds.org\/wp-content\/uploads\/2025\/01\/AAM-2024-Generic-Biosimilar-Medicines-Savings-Report.pdf Accessed 2025 07 04"},{"key":"8153_CR14","unstructured":"Samsung Bioepis (biosimilar market report, 5th edition, Q2 2024)"},{"key":"8153_CR15","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1055\/s-0033-1361111","volume":"76","author":"F H\u00f6rbrand","year":"2014","unstructured":"H\u00f6rbrand F, Rottenkolber D, Fischaleck J, Hasford J (2014) Erythropoietin-induced treatment costs in patients suffering from renal anemia\u2013a comparison between biosimilar and originator drugs. Gesundheitswesen 76:e79\u2013e84","journal-title":"Gesundheitswesen"},{"key":"8153_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update. Endocr Pract 26:1\u201346","journal-title":"Endocr Pract"},{"key":"8153_CR17","doi-asserted-by":"crossref","unstructured":"Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG, Physicians CGCotACo, Cross Jr JT, Fitterman N, Lin JS, Maroto M (2023) Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Annals Intl Medic 176:224\u2013238","DOI":"10.7326\/M22-1034"},{"key":"8153_CR18","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/GME.0000000000001831","volume":"28","author":"MR McClung","year":"2021","unstructured":"McClung MR, Pinkerton J, Blake J, Cosman F, Lewiecki E, Shapiro M (2021) Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause 28:973\u2013997","journal-title":"Menopause"},{"key":"8153_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab 105:587\u2013594","journal-title":"J Clin Endocrinol Metab"},{"key":"8153_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-026-00651-0","author":"J Flanigan","year":"2026","unstructured":"Flanigan J, Kane S, Mirzayeh Fashami F, Zhou A, Almuallem L, Tindal M, Schauf M, Li E, Lyman GH (2026) Cost-effectiveness of biosimilar denosumab versus bisphosphonates in postmenopausal osteoporosis. Pharmacoecon Open. https:\/\/doi.org\/10.1007\/s41669-026-00651-0","journal-title":"Pharmacoecon Open"},{"key":"8153_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","volume":"276","author":"MC Weinstein","year":"1996","unstructured":"Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276:1253\u20131258","journal-title":"JAMA"},{"key":"8153_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316:1093\u20131103","journal-title":"JAMA"},{"key":"8153_CR23","volume-title":"ICER\u2019s reference case for economic evaluations: principles and rationale","author":"Institute for Clinical and Economic Review","year":"2020","unstructured":"Institute for Clinical and Economic Review (2020) ICER\u2019s reference case for economic evaluations: principles and rationale. Institute for Clinical and Economic Review, Boston, MA, USA"},{"key":"8153_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"8153_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster J-Y, Tosteson A, Bukata S, Saag K, Gold D, Halbout P, Jiwa F, Lewiecki EM, Pinto D (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30:45\u201357","journal-title":"Osteoporos Int"},{"key":"8153_CR26","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, Almasri J, Farah W, Sarigianni M, Muthusamy K (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104:1623\u20131630","journal-title":"J Clin Endocrinol Metab"},{"key":"8153_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00198-009-1032-9","volume":"21","author":"B Ettinger","year":"2010","unstructured":"Ettinger B, Black D, Dawson-Hughes B, Pressman A, Lr M (2010) Updated fracture incidence rates for the US version of FRAX\u00ae. Osteoporos Int 21:25\u201333","journal-title":"Osteoporos Int"},{"key":"8153_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res 22:465\u2013475","journal-title":"J Bone Miner Res"},{"key":"8153_CR29","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s00198-004-1643-0","volume":"15","author":"J Kanis","year":"2004","unstructured":"Kanis J, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862\u2013871","journal-title":"Osteoporos Int"},{"key":"8153_CR30","doi-asserted-by":"crossref","unstructured":"Willis MS, Nilsson A, Neslusan CA (2025) A review of heterogeneity in comparative economic analysis, with specific considerations for the decentralized US setting and patient-centered care. PharmacoEconomics 1\u201316","DOI":"10.1007\/s40273-025-01478-z"},{"key":"8153_CR31","first-page":"1089","volume":"25","author":"QA Le","year":"2019","unstructured":"Le QA (2019) Patient-level modeling approach using discrete-event simulation: a cost-effectiveness study of current treatment guidelines for women with postmenopausal osteoporosis. J Manag Care Spec Pharm 25:1089\u20131095","journal-title":"J Manag Care Spec Pharm"},{"key":"8153_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2022.06.007","volume":"26","author":"MH Sch\u00f6ttler","year":"2023","unstructured":"Sch\u00f6ttler MH, Coerts FB, Postma MJ, Boersma C, Rozenbaum MH (2023) The effect of the drug life cycle price on cost-effectiveness: case studies using real-world pricing data. Value Health 26:91\u201398","journal-title":"Value Health"},{"key":"8153_CR33","unstructured":"Amgen (2022) 2022 biosimilar trend report"},{"key":"8153_CR34","first-page":"660","volume":"27","author":"J Qian","year":"2021","unstructured":"Qian J (2021) Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015\u20132018. J Manag Care Spec Pharm 27:660\u2013666","journal-title":"J Manag Care Spec Pharm"},{"key":"8153_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7249\/rhq-07-04-03","volume":"7","author":"AW Mulcahy","year":"2018","unstructured":"Mulcahy AW, Hl\u00e1vka JP, Case SR (2018) Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q 7:3","journal-title":"Rand Health Q"},{"key":"8153_CR36","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.jval.2020.06.014","volume":"23","author":"MC Mouslim","year":"2020","unstructured":"Mouslim MC, Trujillo AJ, Alexander GC, Segal JB (2020) Association between filgrastim biosimilar availability and changes in claim payments and patient out-of-pocket costs for biologic filgrastim products. Value Health 23:1599\u20131605","journal-title":"Value Health"},{"key":"8153_CR37","doi-asserted-by":"publisher","first-page":"e1235","DOI":"10.1200\/OP.20.01047","volume":"17","author":"E Li","year":"2021","unstructured":"Li E, Mezzio DJ, Campbell D, Campbell K, Lyman GH (2021) Primary prophylaxis with biosimilar filgrastim for patients at intermediate risk for febrile neutropenia: a cost-effectiveness analysis. JCO Oncol Pract 17:e1235\u2013e1245","journal-title":"JCO Oncol Pract"},{"key":"8153_CR38","doi-asserted-by":"crossref","unstructured":"Ryder HF, McDonough CM, Tosteson AN, Lurie JD (2009) Decision analysis and cost-effectiveness analysis. Seminars in spine surgery. Elsevier, pp 216\u2013222","DOI":"10.1053\/j.semss.2009.08.003"},{"key":"8153_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.11005\/jbm.2022.29.2.83","volume":"29","author":"J-Y Kang","year":"2022","unstructured":"Kang J-Y, Choi L, Johnson B, Yang H (2022) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in South Korea. J Bone Metab 29:83","journal-title":"J Bone Metab"},{"key":"8153_CR40","unstructured":"National Institute for Health and Clinical Excellence (NICE) (2010) Denosumab for the prevention of osteoporotic fractures in postmenopausal women"},{"key":"8153_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B J\u00f6nsson","year":"2011","unstructured":"J\u00f6nsson B, Str\u00f6m O, Eisman JA, Papaioannou A, Siris E, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967\u2013982","journal-title":"Osteoporos Int"},{"key":"8153_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3111\/13696998.2010.499072","volume":"13","author":"F Borgstr\u00f6m","year":"2010","unstructured":"Borgstr\u00f6m F, Str\u00f6m O, Marin F, Kutahov A, Ljunggren \u00d6 (2010) Cost effectiveness of teriparatide and PTH (1\u201384) in the treatment of postmenopausal osteoporosis. J Med Econ 13:381\u2013392","journal-title":"J Med Econ"},{"key":"8153_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-008-0644-9","volume":"20","author":"O Str\u00f6m","year":"2009","unstructured":"Str\u00f6m O, Borgstr\u00f6m F, Kanis J, J\u00f6nsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23\u201334","journal-title":"Osteoporos Int"},{"key":"8153_CR44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwi\u0144ski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08153-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08153-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08153-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:02:54Z","timestamp":1785510174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08153-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":44,"alternative-id":["8153"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08153-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Edward Li and Marion Schauf are employees of Sandoz Inc. Sarah Kane, Fatemeh Mirzayeh Fashami, and Rebecca McTavish are employed by EVERSANA, which received a consultancy fee for development of this analysis. Stuart Silverman has received consultation fees from Sandoz.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}